title: The prevalence of molecular and immunologic infective markers of hepatitis viruses in patients with hematological malignancies.
abstract: Acute and chronic viral hepatitis infections are corresponding to increase the risk of different types of hematological malignancies especially with leukemia. In this study the serological and molecular markers of hepatitis viruses were evaluated in patients with different types of leukemia in comparing with control group. In this cross sectional study, 100 EDTA-treated blood samples were collected from leukemia patients and also from healthy control group, respectively. Serological and molecular markers of HBV, HCV and HDV viruses were analyzed for determination of the role of these hepatitis viruses in clinical outcomes of leukemia disorders. Increasing risk factors of leukemia were evaluated statistically in two studied groups by SPSS software. One of molecular and immunological markers of HBV, HDV and HCV was found in 24 of 100 (24%), 22 of 100 (22%), and 1 of 100 (1%) patients with leukemia and in 12 of 100 (12%), 6 of 100 (6%), and 2 of 100 (2%) control patients. Significant differences were detected in detection of HBsAg (P = 0.02), HBeAb (P = 0.009), and HCV-RNA (P = 0.05) between leukemia patients and control group, respectively. The high prevalence of HBV and HCV infective markers were detected in ALL and AML patients. Identification of high prevalence of HBV and HCV infective markers in leukemia patients proposed strong association between hepatitis viral infections and leukemia. Therefore, evaluation of the prevalence of viral hepatitis infections in larger groups of patients with long lasting follow up is suggesting.
authors: Shiraz Transplant Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
authors: Mitra
authors: M
authors: Mirzaee
authors: Ramin
authors: R
authors: Yaghobi
authors: Mani
authors: M
authors: Ramzi
authors: Mahdi
authors: M
authors: Roshan Nia
references: Eur J Pediatr. 1994 Apr;153(4):271-5
references: 8194562
references: Blood. 1996 May 15;87(10):4296-301
references: 8639788
references: Blood. 1996 Feb 1;87(3):1202
references: 8562950
references: Br J Haematol. 1995 Oct;91(2):480-2
references: 8547099
references: Blood. 1999 Dec 15;94(12):4046-52
references: 10590048
references: J Med Life. 2010 Jul-Sep;3(3):320-9
references: 20945824
references: J Clin Pathol. 1996 Mar;49(3):230-32
references: 8675735
references: Blood. 1997 Dec 1;90(11):4628-33
references: 9373275
references: J Med Virol. 2000 Nov;62(3):299-307
references: 11055239
references: Pediatr Infect Dis J. 1996 Mar;15(3):265-6
references: 8852917
references: Med Pediatr Oncol. 2003 Feb;40(2):104-10
references: 12461794
references: Int J Infect Dis. 2006 Nov;10(6):453-7
references: 17000127
references: Blood. 1997 Aug 1;90(3):1315-20
references: 9242567
references: Med Sci Monit. 2002 Apr;8(4):CR274-9
references: 11951070
references: Haematologica. 2004 Jan;89(1):70-6
references: 14754608
references: Blood. 1999 Jun 1;93(11):3672-7
references: 10339473
references: Cancer Epidemiol Biomarkers Prev. 2008 Nov;17(11):3069-75
references: 18957521
references: Ann Hematol. 2002 Jan;81(1):48-9
references: 11807636
references: Transfusion. 1995 Apr;35(4):313-8
references: 7701549
references: J Clin Microbiol. 1998 Oct;36(10):3040-3
references: 9738063
references: J Med Virol. 1999 Jun;58(2):139-44
references: 10335861
references: Lancet. 1995 Mar 11;345(8950):603-7
references: 7898176
references: Bone Marrow Transplant. 2005 Mar;35(6):595-9
references: 15665849
references: Blood. 1993 Oct 15;82(8):2564-7
references: 7691264
references: Am J Hematol. 1997 Jun;55(2):77-82
references: 9209002